Clinical Trials Logo

MTOR Activating Mutation clinical trials

View clinical trials related to MTOR Activating Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT03190174 Completed - Colorectal Cancer Clinical Trials

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Start date: August 24, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mTOR inhibitor ABI-009 in advanced Ewing's sarcoma, PEComa, epithelioid sarcoma, desmoid tumor, chordoma, non-small cell lung cancer, small cell lung cancer, urethelial carcinoma, melanoma, renal cell carcinoma, squamous cell carcinoma of head and neck, hepatocellular carcinoma, classical Hodgkin's lymphoma, MSI-H/dMMR metastatic colorectal cancer, and tumors with genetic mutations sensitive to mTOR inhibitors